
    
      This is a multicenter, open label, 4-week study. Study subjects are defined in Chinese Han
      nationality patients with acute mania of bipolar disorder (inpatients or outpatients). The
      screening phase is up to 7 days. The eligible patients in the screening phase can be enrolled
      into the treatment phase, the target dose is 400-800mg/day, and treatment period will last
      for 4 weeks. The objective is to evaluate the efficacy of quetiapine fumarate switching from
      other drugs used as monotherapy in the treatment of acute mania with bipolar disorder, and
      the relationship between the serum BDNF and quetiapine fumarate.
    
  